Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition....
Main Authors: | Matthias Pauschinger, F. Stephen Hodi, Patrick A. Ott, Thomas F. Gajewski, Hussein Tawbi, Jason J. Luke, Lucie Heinzerling, Aliya N. Husain, Azadeh Tajmir-Riahi, Evan J. Lipson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2016-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/4/1/50.full |
Similar Items
-
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
by: Firas Y. Kreidieh, et al.
Published: (2023-07-01) -
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
by: Priyanka B. Subrahmanyam, et al.
Published: (2018-03-01) -
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
by: Weishi Cheng, et al.
Published: (2024-07-01) -
Polyglandular Autoimmune Syndrome Triggered after CTLA-4 and PD-1L Immunotherapy Treatment
by: Juan Luis Fernández-Morera, et al.
Published: (2021-01-01)